Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 854,519
  • Shares Outstanding, K 63,961
  • Annual Sales, $ 262,600 K
  • Annual Income, $ -80,800 K
  • EBIT $ -119 M
  • EBITDA $ -122 M
  • 60-Month Beta 1.87
  • Price/Sales 3.26
  • Price/Cash Flow N/A
  • Price/Book 1.98

Options Overview Details

View History
  • Implied Volatility 101.49% (-15.82%)
  • Historical Volatility 54.64%
  • IV Percentile 84%
  • IV Rank 29.22%
  • IV High 219.59% on 02/13/26
  • IV Low 52.74% on 08/25/25
  • Expected Move (DTE 16) 2.04 (14.83%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 65
  • Volume Avg (30-Day) 172
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 5,947
  • Open Int (30-Day) 5,376
  • Expected Range 11.72 to 15.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.94
  • Number of Estimates 8
  • High Estimate -0.71
  • Low Estimate -1.21
  • Prior Year 1.14
  • Growth Rate Est. (year over year) -182.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +25.09%
on 02/24/26
14.00 -1.71%
on 02/10/26
+0.37 (+2.76%)
since 02/04/26
3-Month
11.00 +25.09%
on 02/24/26
14.14 -2.69%
on 02/03/26
+1.21 (+9.64%)
since 12/04/25
52-Week
5.90 +133.22%
on 05/15/25
18.93 -27.31%
on 03/06/25
-2.76 (-16.71%)
since 03/04/25

Most Recent Stories

More News
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – ...

ARVN : 13.76 (+2.99%)
Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 13.76 (+2.99%)
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 13.76 (+2.99%)
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb....

ARVN : 13.76 (+2.99%)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

DGX : 208.45 (+0.04%)
EXAS : 103.50 (+0.13%)
ILMN : 128.97 (-0.46%)
ARVN : 13.76 (+2.99%)
PFE : 26.62 (+0.15%)
QTRX : 5.86 (-0.17%)
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma...

ARVN : 13.76 (+2.99%)
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 13.76 (+2.99%)
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 13.76 (+2.99%)
PFE : 26.62 (+0.15%)
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust...

ARVN : 13.76 (+2.99%)
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc . (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 13.76 (+2.99%)

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 14.66
2nd Resistance Point 14.30
1st Resistance Point 14.03
Last Price 13.76
1st Support Level 13.39
2nd Support Level 13.03
3rd Support Level 12.76

See More

52-Week High 18.93
Fibonacci 61.8% 13.95
Last Price 13.76
Fibonacci 50% 12.41
Fibonacci 38.2% 10.88
52-Week Low 5.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar